Cargando…
Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain
Dysregulation of ErbB-family signaling underlies numerous pathologies and has been therapeutically targeted through inhibiting ErbB-receptors themselves or their cognate ligands. For the latter, “decoy” antibodies have been developed to sequester ligands including heparin-binding epidermal growth fa...
Autores principales: | Miller, Miles A., Moss, Marcia L., Powell, Gary, Petrovich, Robert, Edwards, Lori, Meyer, Aaron S., Griffith, Linda G., Lauffenburger, Douglas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609913/ https://www.ncbi.nlm.nih.gov/pubmed/26477568 http://dx.doi.org/10.1038/srep15150 |
Ejemplares similares
-
Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia
por: Díaz, Begoña, et al.
Publicado: (2013) -
Alternative mRNA Splicing Generates Two Distinct ADAM12 Prodomain Variants
por: Duhachek-Muggy, Sara, et al.
Publicado: (2013) -
Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates
por: Yoneyama, Toshie, et al.
Publicado: (2017) -
ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker
por: Yoneyama, Toshie, et al.
Publicado: (2018) -
ADAM 12: A Putative Marker of Oligodendrogliomas?
por: Kanakis, Dimitrios, et al.
Publicado: (2013)